BN 02/19 21:46 *SANOFI NAMES OLIVIER BRANDICOURT CEO
BN 02/19 21:46 *SANOFI: BRANDICOURT TO TAKE UP NEW DUTIES ON APRIL 2, '15
BN 02/19 21:46 *SANOFI: BRANDICOURT HAD BEEN CHAIRMAN OF BAYER HEALTHCARE AG
BFW 02/19 21:46 *SANOFI: SANOFI NAMES OLIVIER BRANDICOURT AS CEO
BN 02/19 21:45 *SANOFI: TENURE AS CEO WILL BEGIN ON APRIL 2, '15
BN 02/19 21:45 *SANOFI: SANOFI NAMES OLIVIER BRANDICOURT AS CEO
BN 02/19 21:45 *SANOFI NAMES OLIVIER BRANDICOURT AS CEO
BN 02/19 21:46 *SANOFI: BRANDICOURT TO TAKE UP NEW DUTIES ON APRIL 2, '15
BN 02/19 21:46 *SANOFI: BRANDICOURT HAD BEEN CHAIRMAN OF BAYER HEALTHCARE AG
BFW 02/19 21:46 *SANOFI: SANOFI NAMES OLIVIER BRANDICOURT AS CEO
BN 02/19 21:45 *SANOFI: TENURE AS CEO WILL BEGIN ON APRIL 2, '15
BN 02/19 21:45 *SANOFI: SANOFI NAMES OLIVIER BRANDICOURT AS CEO
BN 02/19 21:45 *SANOFI NAMES OLIVIER BRANDICOURT AS CEO
Sanofi: Sanofi Appoints Olivier Brandicourt as Chief Executive Officer
2015-02-19 21:45:48.350 GMT
Sanofi Appoints Olivier Brandicourt as Chief Executive Officer
class="hugin">
- Tenure as CEO will commence on April 2, 2015 -
Paris - February 19, 2015 - The Board of Directors unanimously appointed
Olivier Brandicourt as Chief Executive Officer of Sanofi.
Olivier Brandicourt has 28 years of global experience in the pharmaceutical
industry, most recently as Chairman of the Board of Management of Bayer
HealthCare AG and member of the Executive Council of Bayer AG. Previously,
Brandicourt held numerous positions of increasing responsibility within major
global pharmaceutical groups, such as Parke-Davis/Warner-Lambert and Pfizer.
Notably, Brandicourt served as a member of Pfizer's global Executive
Leadership Team from 2010 - 2013.
A physician by training, Olivier Brandicourt's career includes several senior
positions in Europe,
Canada and the United States. As the head of various key healthcare divisions,
he has a broad range of expertise and knowledge of the pharmaceutical industry
and has led the launch of numerous new medicines and the completion of
strategic acquisitions and integrations.
Serge Weinberg, Chairman of the Board of Directors, Sanofi said, "Sanofi
undertook a rigorous selection process to identify the right person to lead
Sanofi forward at an important time for our company. I am very pleased that
Olivier Brandicourt will be the next chief executive officer of Sanofi.
Olivier Brandicourt's strong experience combined with his international
profile, deep knowledge of U.S. and emerging healthcare markets, and his
capability to unite teams will provide new dynamism to Sanofi's strategy of
diversification and innovation."
In agreement with his former employer, Brandicourt will take up his new duties
on April 2, 2015.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's and MannKind's management teams believe that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi and MannKind, that could cause actual
results and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties inherent
in research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as their
decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi and MannKind,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F
for the year ended December 31, 2013, and those risks and uncertainties listed
in MannKind's annual report on Form 10-K for the year ended December 31, 2013,
and listed or described in subsequent reports filed by MannKind with the
Securities and Exchange Commission. Other than as required by applicable law,
neither Sanofi nor MannKind undertake any obligation to update or revise any
forward-looking information or statements.
Contacts:
Media Relations Investor Relations
Gregory Miley Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
MR@sanofi.com ir@sanofi.com
Image Sept
Florence Coupry
fcoupry@image7.com
+33 6 63 44 27 59
Link to PDF version
2015-02-19 21:45:48.350 GMT
Sanofi Appoints Olivier Brandicourt as Chief Executive Officer
class="hugin">
- Tenure as CEO will commence on April 2, 2015 -
Paris - February 19, 2015 - The Board of Directors unanimously appointed
Olivier Brandicourt as Chief Executive Officer of Sanofi.
Olivier Brandicourt has 28 years of global experience in the pharmaceutical
industry, most recently as Chairman of the Board of Management of Bayer
HealthCare AG and member of the Executive Council of Bayer AG. Previously,
Brandicourt held numerous positions of increasing responsibility within major
global pharmaceutical groups, such as Parke-Davis/Warner-Lambert and Pfizer.
Notably, Brandicourt served as a member of Pfizer's global Executive
Leadership Team from 2010 - 2013.
A physician by training, Olivier Brandicourt's career includes several senior
positions in Europe,
Canada and the United States. As the head of various key healthcare divisions,
he has a broad range of expertise and knowledge of the pharmaceutical industry
and has led the launch of numerous new medicines and the completion of
strategic acquisitions and integrations.
Serge Weinberg, Chairman of the Board of Directors, Sanofi said, "Sanofi
undertook a rigorous selection process to identify the right person to lead
Sanofi forward at an important time for our company. I am very pleased that
Olivier Brandicourt will be the next chief executive officer of Sanofi.
Olivier Brandicourt's strong experience combined with his international
profile, deep knowledge of U.S. and emerging healthcare markets, and his
capability to unite teams will provide new dynamism to Sanofi's strategy of
diversification and innovation."
In agreement with his former employer, Brandicourt will take up his new duties
on April 2, 2015.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's and MannKind's management teams believe that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi and MannKind, that could cause actual
results and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties inherent
in research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as their
decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi and MannKind,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F
for the year ended December 31, 2013, and those risks and uncertainties listed
in MannKind's annual report on Form 10-K for the year ended December 31, 2013,
and listed or described in subsequent reports filed by MannKind with the
Securities and Exchange Commission. Other than as required by applicable law,
neither Sanofi nor MannKind undertake any obligation to update or revise any
forward-looking information or statements.
Contacts:
Media Relations Investor Relations
Gregory Miley Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
MR@sanofi.com ir@sanofi.com
Image Sept
Florence Coupry
fcoupry@image7.com
+33 6 63 44 27 59
Link to PDF version